Stereotaxis, Inc. (STXS)
| Market Cap | 174.08M +13.5% |
| Revenue (ttm) | 32.38M +20.3% |
| Net Income | -22.91M |
| EPS | -0.25 |
| Shares Out | 97.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 645,015 |
| Open | 1.820 |
| Previous Close | 1.820 |
| Day's Range | 1.760 - 1.890 |
| 52-Week Range | 1.540 - 3.590 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+123.46%) |
| Earnings Date | Mar 9, 2026 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Na... [Read more]
Financial Performance
In 2025, Stereotaxis's revenue was $32.38 million, an increase of 20.28% compared to the previous year's $26.92 million. Losses were -$22.91 million, -9.62% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 123.46% from the latest price.
News
Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks
Stereotaxis targets early-stage endovascular robotics with differentiated magnetic navigation for electrophysiology and other minimally invasive procedures. Their MAGiC catheter recently received FDA ...
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Stereotaxis Reports 2025 Full Year Financial Results
ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program
ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of ...
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U....
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the compa...
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
Stereotaxis, Inc. ( STXS) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants David Fischel - CEO & Chairman Kimberly Peery - Chief Financial Officer Conference Call Participants...
Stereotaxis Reports 2025 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance
ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it receiv...
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs
ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE...
Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and Car...
Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System
ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful fi...
First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successfu...
Stereotaxis to Present at Upcoming Investor Conferences
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi...
Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology...
Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David Leo Fischel - CEO & Chairman Kimberly R. Peery - Chief Financial Officer Conference...
Stereotaxis Reports 2025 Second Quarter Financial Results
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...
Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter
ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has re...
Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock
ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has e...
Stereotaxis: Recurring Revenue Inflection
I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin dispo...
First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology
ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publicatio...
Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Partic...